secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001867096-24-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris expects Q4 cashflow positive, 2023 revenue at high end of $160M-$165M
---------------------------------------------------------------------------

- Total revenue for FY 2023 expected at high end of prior $160M-$165M guidance.
- Ending cash, equivalents & short-term investments >$72M, above $65M-$70M guidance.
- Q4 2023 expected to be cashflow positive; Q4 & FY results on or about March 6, 2024.
- 2024 outlook: revenue growth, flat opex, declining burn, sufficient cash for obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000003/0001867096-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000003/xers-20240104.htm
  HTML page:      https://secwatch.observer/filing/0001867096-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer